Close
CDMO Safety Testing 2026
Novotech

LabConnect Announces Global Sample Processing Network

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
- Advertisement -

LabConnect, a leading global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organizations, is pleased to announce a new service: LabConnect’s global sample processing network (GSPN).

This GSPN will offer a comprehensive global solution for sample preparation and processing requirements.

Given the rapid growth in immuno-oncology and cell gene therapies, high-quality and expeditious sample processing is required within today’s trials. Balancing turnaround time requirements with the desire for processing consistency across global sites is an industry-wide challenge.

With more worldwide locations than any other central laboratory services provider, LabConnect addresses this challenge by significantly minimizing shipping time from site to processing lab, optimizing viability for time-sensitive samples. Proprietary packaging, standardized analyst certification and centralized performance monitoring combine to ensure global consistency. Additionally, LabConnect’s web portal allows easy access to study-wide sample processing quality metrics. LabConnect’s GSPN supports global research protocols by offering reliable worldwide sample processing.

Jeff Mayhew, chief development officer at LabConnect says, “LabConnect has recognized the growing need for high quality sample processing in the industry’s increasingly complex studies. GSPN is our innovative approach to addressing these evolving demands. GSPN combines our extensive global footprint with our global expertise in sample processing, offering the unique ability to meet the most challenging of study requirements.”

About LabConnect
Founded in 2002, LabConnect comprises a network of global central laboratories with services including routine and esoteric laboratory testing, clinical kit building, sample management, biorepository, and scientific operations support services for biopharmaceutical, medical device, and contract research organizations around the world. Learn more at labconnectllc.com

Latest stories

Related stories

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »